{"id":"sng001","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Cough"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201562","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by activating the JAK-STAT signaling pathway, which leads to the production of antiviral proteins and the recruitment of immune cells to the site of infection. This helps to reduce the severity and duration of respiratory illnesses such as COVID-19.","oneSentence":"SNG001 is an inhaled interferon beta-1a, which works by stimulating the body's immune response to fight off respiratory viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:03.403Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT06999603","phase":"PHASE2","title":"Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection","status":"RECRUITING","sponsor":"Synairgen Research Ltd.","startDate":"2025-09-02","conditions":"Viral Pneumonia","enrollment":550},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT04732949","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2021-01-12","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19","enrollment":623},{"nctId":"NCT03570359","phase":"PHASE2","title":"A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2018-01-29","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":122},{"nctId":"NCT04385095","phase":"PHASE2","title":"Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2020-03-16","conditions":"SARS-CoV-2","enrollment":221},{"nctId":"NCT01126177","phase":"PHASE2","title":"Comparing Efficacy and Safety of Inhaled SNG001 to Placebo","status":"COMPLETED","sponsor":"Synairgen Research Ltd.","startDate":"2010-03","conditions":"Asthma","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SNG001","genericName":"SNG001","companyName":"Synairgen Research Ltd.","companyId":"synairgen-research-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SNG001 is an inhaled interferon beta-1a, which works by stimulating the body's immune response to fight off respiratory viruses. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}